Abdel-Mequit TA et al (2010) Botulinum toxin-A injections into neurogenic overactive bladder – to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 184(6):2423–2427. CrossRef
CrossRefApostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174:977–983 PubMed CrossRef
Apostolidis A, Dasgupta P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunction: a European Consensus panel record. Eur Urol 55:100–120 PubMed CrossRef
Blackburn SC, Jones C, Bedoya S, Steinbrecher HA, Malone PS, Griffin SJ (2012) Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children. J Pediatr Urol 9(6 PT A):697–970
Bock S, Folie P, Wolff K et al (2010) First experiences with pudendal nerve stimulation in fecal incontinence: a technical report. Tech Coloproctol 14(1):41–44 PubMed CrossRef
Bosch JL (2010) An update on sacral neuromodulation: where do we stand with this in the management of lower urinary tract dysfunction in 2010? BJU Int 106:1432–1442 PubMed CrossRef
Coelho A, Dinis P, Pinto R et al (2010) Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol 57(5):884–890 PubMed CrossRef
Cruz F, Herschorn S et al (2011) Efficacy and saftey of onabotulinumtoxina in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trail. Eur Urol 60(4):742–750 PubMed CrossRef
Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ (2005) Changes in brain activity following sacral neuromodulation for urinary retention. J Urol 174:2268–2272 PubMed CrossRef
Dmochowski R et al (2010) Efficacy and safety of onabotulinumtoxin A for idiopathic overactive bladder: a double-blind, placebo-controlled, randomized, dose ranging trial. J Urol 184(6):2416–2422 PubMed CrossRef
Dolly O (2003) Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 43(Suppl1):16–24 CrossRef
Domurath B, Böthig R, Bremer J, Kaufmann A, Pannek J (2014) manual zur neuro-urologischen Diagnostik und Therapie Querschnittgelähmter, Jachmann
Dykstra DD, Sidi AA (1990) Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71(1):24–26. PubMed
PubMedFowler CJ, Christmas TJ, Chapple CR et al (1988) Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome? BMJ 297:1436–1438. PubMedCentral PubMed CrossRef
PubMedPubMedCentralCrossRefGiannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M (2006) Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 49(4):704–709. PubMed CrossRef
PubMedCrossRefGiannantoni A, Porena M, Costantini E et al (2008) Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 179(3):1031–1034. PubMed CrossRef
PubMedCrossRefGiannantoni A, Cagini R, Del Zingaro M et al (2010) Botulinum A toxin intravesical injections for painful bladder syndrome: impact upon pain, psychological functioning and Quality of Life. Curr Drug Deliv 7(5):442–446. PubMed CrossRef
PubMedCrossRefGottsch HP, Miller JL, Yang CC, Berger RE (2011) A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol Urodyn 30(1):93–96. PubMed CrossRef
PubMedCrossRefGroen J, Ruud Bosch JL, van Mastrigt R (2006) Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding. J Urol. 175:1005–1009, discussion 1009 PubMed CrossRef
Haferkamp A, Schurch B, Reitz A et al (2004) Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 46(6):784–791. PubMed CrossRef
PubMedCrossRefHoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen P, Van Laecke EJ (2006) The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 176(1):328–330. CrossRef
PubMedCrossRefHuwyler M, Kiss G, Burkhard FC (2009) Microbiological tined-lead examination: does prolonged sacral neuromodulation testing induce infection? BJU Int 104:646–650. discussion 650 PubMed CrossRef
PubMedCrossRefJonas U, Fowler CJ, Chancellor MB et al (2001) Efficacy of sacral nerve stimulation for urinary retention: results18 months after implantation. J Urol 165:15–19. PubMed CrossRef
PubMedCrossRefKajbafzadeh AM, Moosavi S, Tajik P et al (2006) Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology 68:1091–1096. PubMed CrossRef
PubMedCrossRefKerner J (1822) Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus. Cotta, Stuttgart
Kessler TM, Fowler C (2008) Sacral neuromodulation for urinary retention. Nat Clean Pract Urol 5:657–666. CrossRef
CrossRefKessler TM, Madersbacher H, Kiss G (2005) Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection method? Eur Urol 47:660–665
PubMedCrossRefKessler TM, Burkhard FC, Maderbacher H et al (2008) Saftey of prolonged sacral neuromodulation tined lead testing. Curr Med Res Opin 24:343–347. PubMed CrossRef
PubMedCrossRefKessler TM, La Framboise D, Trelle S et al (2010) Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol 58:865–874. PubMed CrossRef
PubMedCrossRefKhera M, Somogyi GT, Kiss S (2004) Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 45(7):987–993
PubMedCrossRefLahdes-Vasama TT, Anttila A, Wahl E, Taskinen S (2011) Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study. Scand J Urol Nephrol 45(6):397–400. PubMed CrossRef
PubMedCrossRefLee CL, Kuo HC (2013) Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis. Pain Physician 16(2):109–116. PubMed
PubMedLeng WW, Chancellor MG (2005) How sacral nerve stimulation neuromodulation works. Urol Clin North Am 32:11–18. PubMed CrossRef
PubMedCrossRefMarte A, Borrelli M, Sabatino MD et al (2010) Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children. Eur J Pediatr Surg 20(3):153–157. PubMed CrossRef
PubMedCrossRefMcDowell DT, Noone D, Tareen F, Waldron M, Quinn F (2012) Urinary incontinence in children: botulinum toxin is a safe and effective treatment option. Pediatr Surg Int 28(3):315–320. PubMed CrossRef
PubMedCrossRefOelke M, Bachmann A, Descazeaud A et al (2013) JJ EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140. PubMed CrossRef
PubMedCrossRefOphoven VA, Pannek J (2012) Die Zukunft der invasiven Neuromodulation. Urologe 51:210–216
Pascalei MP, Musiello G, Boldrini R et al (2011) Effects of botulinum toxin type A in the bladder wall of children with neurogenic bladder dysfunction: a comparsion of histological features before and after injection. J Urol 185(6 Suppl):2552–2557. CrossRef
CrossRefPeters KM, Feber KM, Bennet RC (2005) Sacral versus pudendal nerve stimulation for voiding dysfunction: a prospective, single-blinded, randomized Cross-over trial. Neurourol Urodyn 24(7):643–647. PubMed CrossRef
PubMedCrossRefPossover M, Baekelandt J, Chiantera V (2007) The laparoscopic approach to control intractable pelvic neuralgia: from laparoscopic pelvic neurosurgery to the LION procedure. Clin J Pain 23:821–825. PubMed CrossRef
PubMedCrossRefPossover M, Schurch B, Henle KP (2010) New strategies of pelvic nerves stimulation for recovery of pelvic visceral functions an locomotion in paraplegics. Neurourol Urodyn 29:1433–1438. PubMed CrossRef
PubMedCrossRefRapp DE, Turk KW, Bales GT et al (2006) Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175(3 Pt 1):1138–1142. PubMed CrossRef
PubMedCrossRefSchröder A, Thüroff JW (2010) New strategies for medical management of overactive bladder in children. Curr Opin Urol 20(4):313–317. PubMed CrossRef
PubMedCrossRefSchulte-Baukloh H (2012) Botulinumtoxin bei neurogener Blasenfunktionsstörung. Urologe 51:198–203. PubMed CrossRef
CrossRefSchulte-Baukloh H, Knispel HH et al (2005) Repeated botulinum-A toxin injection in treatment of children with neurogenic detrusor overactivity. Urology 66:865–870. PubMed CrossRef
PubMedCrossRefSchulte-Baukloh H, Bigalke H, Miller K et al (2008) Botulinom neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 15:407–415. PubMed CrossRef
PubMedCrossRefSchurch B, Corcos J (2005) Botulinum toxin injections for paediatric incontinence. Curr Opin Uro 15(4):264–267. CrossRef
CrossRefSchurch B, Stöhrer M, Kramer G et al (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164(3 Pt 1):692–697. PubMed CrossRef
PubMedSpinelli M, Sievert KD (2008) Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety. Eur Urol 54:1287–1296. PubMed CrossRef
PubMedCrossRefSpinelli M et al (2005) A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder:description of the method and preliminary data. Neurourol Urodyn 24(4):305–309. PubMed CrossRef
PubMedCrossRefStöhrer M, Schurch B, Kramer G, Schmid D, Gaul G, Hauri D (1999) Botulinim A-Toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedure? Neurourol Urodyn 18:401–402. CrossRef
CrossRefTanagho EA, Schmidt RA (1988) Electrical stimulation in the clinical management of the neurogenic bladder. J Urol 140:1331–1339. PubMed
PubMedCrossRefTirumuru S, Al-Kurdi D, Latthe P (2010) Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review. Int Urogynecol J 21(10):1285–1300. PubMed CrossRef
PubMedCrossRef